

30 September 2022

## Commencement of U.S. Trading on OTCQB

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, is pleased to announce the commencement of U.S. trading in Respiri's shares on the OTCQB under the ticker "RSHUF".

Trading on the OTCQB will simplify trading and enhance liquidity for investors in North America, a key focus market for Respiri as it continues to roll out its innovative wheezo® device and eHealth App across the US.

Material advantages of the OTCQB trading of Respiri's shares include:

1. Trading and settlement in US dollars (USD);
2. Trading in the North American time zone; and
3. Streamlined access for North American based investors.

The OTCQB Venture Market is for entrepreneurial and development stage U.S. and international companies. Trading on OTCQB is intended to enhance the visibility and accessibility of Respiri to U.S. investors, supporting greater liquidity in Respiri's shares in addition to the Company's existing ASX listing.

EAS Advisors LLC acted as Respiri's US corporate adviser. B. Riley Securities acted as Respiri's OTCQB sponsor.

Marjan Mikel, CEO of Respiri said, “This is another step on our roll out and increased focus on the US market. We are excited that we have commenced trading on the OTCQB, allowing Respiri's shares to be traded in USD for the convenience of North American investors. Respiri's shares trading on the OTCQB provide North American investors with further exposure to Respiri at an opportune time as we continue to make inroads into our targeted market in the US.”

**For further information, investors and media please contact:**

**Mr Marjan Mikel**

CEO & Managing Director

Respiri Limited

P: +61 408 462 873

E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**

Executive Chairman

Respiri Limited

P: +61 447 074 160

E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

wheezo® is a registered trademark of Respi Limited.

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.